CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03407976
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:39.162852+00:00
Published At: 2020-07-15T00:00:00+00:00
Record Updated At: 2020-07-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Malignancies", "Urothelial Carcinoma", "MSI-H or dMMR Solid Tumors", "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-07-15"
protocolSection.identificationModule.nctId: "NCT03407976"
protocolSection.identificationModule.officialTitle: "A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.